Ranibizumab Yields 15-Letter Gain In VA In Patients Treated For DME, Study Shows
Results of the second of two phase 3 clinical trials showed that ranibizumab met its primary endpoint in patients being treated for diabetic macular edema, according to a news release from Genentech.